What tirzepatide is
Tirzepatide is a synthetic 39-amino-acid peptide that activates two incretin receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Its backbone is based on the native GIP sequence rather than on GLP-1, with modifications that confer GLP-1 receptor activity and a C20 fatty-diacid conjugate that extends circulating half-life through albumin binding.
It occupies a specific position in the development sequence of this compound class: after single GLP-1 agonists such as semaglutide, and before triple agonists such as retatrutide. That position is what makes it the standard comparator in the literature.
Molecular profile
| Property | Value |
|---|---|
| Development code | LY3298176 |
| CAS number | 2023788-19-2 |
| Receptor targets | GIPR, GLP-1R |
| Molecular formula | C225H348N48O68 |
| Molecular weight | ~4,813 Da |
| Length | 39 amino acids |
| Modification | C20 fatty-diacid conjugation |
| Appearance | White to off-white lyophilised powder |
The dual-agonist rationale
GIP and GLP-1 are the two principal incretin hormones — both released from the gut in response to nutrient intake, both potentiating glucose-dependent insulin secretion. They act through distinct receptors with distinct tissue distributions, and GIP receptors are present in adipose tissue and the central nervous system in ways GLP-1 receptors are not.
The dual-agonist premise is that these pathways are complementary rather than redundant: engaging both produces effects that pushing harder on either alone does not. Tirzepatide is unusual in being an imbalanced agonist — its activity is not equal at the two receptors — and characterising that imbalance is a substantial part of the in-vitro literature around it.
Research context
Tirzepatide is used in receptor pharmacology as a tool compound for probing GIPR/GLP-1R co-activation: binding and selectivity assays, cAMP accumulation readouts, β-arrestin recruitment, and receptor internalisation studies that examine how biased signalling at the two receptors contributes to the overall profile. In metabolic models it serves as the reference dual agonist against which single and triple agonists are compared.
Supplied for in-vitro laboratory research only. No therapeutic claim is made and no dosing or administration guidance is provided.
Analytical notes
Tirzepatide sits in a family of closely related, similarly sized, similarly lipidated incretin analogues, which makes identity confirmation by mass spectrometry non-negotiable. The compounds in this class have overlapping retention behaviour on reversed-phase chromatography, so a clean single peak does not by itself establish which analogue you have. Observed mass against theoretical mass does.
This matters commercially as well as scientifically. Substitution within this class — supplying a cheaper analogue against an order for a more expensive one — is only detectable by mass, and a Certificate of Analysis carrying purity but no mass confirmation cannot rule it out. See what mass spectrometry establishes that HPLC cannot.
On the purity side, the impurities of interest are single-residue deletion sequences and incompletely conjugated species, both of which elute close to the main peak. The integration window matters, which is why the chromatogram is worth more than the percentage extracted from it.
Handling and storage
Store sealed at −20 °C, protected from light and moisture. Bring to room temperature before opening. As with all fatty-acid-conjugated peptides, add diluent down the vial wall and swirl rather than shake — the lipophilic tail drives accumulation at the air-liquid interface, where aggregation begins. Store reconstituted solution at 2–8 °C and avoid repeated freeze-thaw.
What we supply
Released against a ≥99% purity specification, with HPLC purity and mass spectrometry identity confirmation on every batch and a batch-specific Certificate of Analysis. Select batches additionally receive independent third-party purity verification.